Its CSF and plasma levels are increased across the AD continuum, correlating with tau-PET burden but not with Aβ pathology [104], and have been shown to discriminate between normal and mildly impaired cognitive individuals with 85% sensitivity and specificity [105], although it proved less useful for monitoring disease progression. The gene discussed is MAPT; the disease is Alzheimer disease.